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Objectives: Administering outpatient parenteral antimicrobial therapy in the community setting
(CoPAT) is becoming more common with the increasing emphasis on controlling costs. However, few
controlled trials have evaluated this treatment modality.
Methods: Using data from a recent randomized trial comparing daptomycin with standard therapy
(semi-synthetic penicillin or vancomycin, each with initial low-dose gentamicin) for Staphylococcus
aureus bacteraemia and infective endocarditis (SAB/IE), patient characteristics and outcomes were
evaluated. Patients receiving their full course of therapy in the hospital setting were compared with
those who received some portion outside of the hospital (CoPAT).
Results: Among the 200 patients, 51.5% received CoPAT. These patients were generally younger
(median age 50 versus 54 years, P50.028). In the CoPAT group, there tended to be fewer patients with
endocardial involvement (8.7% versus 18.6%, P50.061) and pre-existing valvular heart disease (7.8%
versus 15.5%, P50.120). CoPAT patients received longer therapy courses (mean 25.4 versus 13.5 days,
P<0.001) and had higher rates of therapy completion (90.3% versus 45.4%, P<0.001) and clinical
success (86.4% versus 55.7%, P<0.001). Persisting or relapsing S. aureus was less frequent in the
CoPAT group (3.9% versus 15.5%, P50.007) and there were fewer deaths (3.9% versus 18.6%,
P50.001) 6 weeks after the end of therapy. Hospital readmission occurred for 18 of the 103 (17.5%)
CoPAT patients. Clinical success rates were similar for CoPAT patients receiving daptomycin (90.0%)
or standard therapy (83.0%).
Conclusions: With proper monitoring, stable patients can complete treatment for SAB/IE as outpatients
in the community setting. Daptomycin is an appropriate option for this setting.
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Introduction
Staphylococcus aureus bacteraemia (SAB) is a serious infection
associated with signiﬁcant complications, including infective
endocarditis (IE) and other metastatic deep tissue infections as
well as high rates of mortality.
1–5 Rates of infection caused by
methicillin-resistant S. aureus (MRSA) are increasing,
6 and
MRSA infections are associated with a greater risk of compli-
cations than are those due to methicillin-susceptible isolates.
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patients with MRSA bacteraemia than in those with methicillin-
susceptible S. aureus (MSSA) bacteraemia.
3,4
Patients with SAB/IE are likely to receive intravenous (iv)
antimicrobial therapy for up to 4–6 weeks. An increasing focus
on hospital costs and pressure to free up expensive hospital beds
have motivated clinicians to seek alternative therapeutic
approaches, including community-based outpatient parenteral
antimicrobial therapy (CoPAT). Numerous reports describing the
use of CoPAT in a broad cross-section of patient populations
support the notion that selected patients with SAB/IE—in par-
ticular, those who have stabilized in the hospital—may be candi-
dates for the completion of therapy in a community setting.
7–10
Typical community-based settings involve home treatment as
well as treatment at nursing facilities, assisted-living facilities
and rehabilitation centres. Although most studies of outpatient
parenteral antimicrobial therapy (OPAT) involve registries, or
are otherwise retrospective in nature, the available data show
that cure rates are generally .90% for bacterial infections of all
kinds.
8,9,11
While OPAT studies are plentiful, there is a paucity of data
from controlled clinical trials. The recently completed prospec-
tive, randomized trial comparing daptomycin with standard
therapy for SAB/IE captured detailed data on patients treated
both inside and outside the hospital setting. In this study, stan-
dard therapy, against which daptomycin treatment was com-
pared, consisted of a semi-synthetic penicillin or vancomycin,
each with 4 days of initial low-dose gentamicin [1 mg/kg every
8 h, adjusted as appropriate for creatinine clearance (CLCR)].
12
The unique database generated during the course of the ran-
domized trial provides an opportunity to assess the impact of
treatment setting on patients being treated for a serious infection.
Therefore, we conducted a further analysis of the data to
examine the clinical course of patients who completed their anti-
biotic therapy in the hospital compared with those who received
some portion in the CoPAT setting.
Methods
Using data from the open-label, randomized, controlled trial of dap-
tomycin versus standard therapy (semi-synthetic penicillin or vanco-
mycin, each with initial low-dose gentamicin) for SAB/IE,
12 the
characteristics and outcomes of patients were evaluated based on
treatment setting during administration of iv antimicrobial therapy.
The randomized clinical trial is registered with ClinicalTrials.gov
(NCT00093067). The protocol, approved by the Institutional Review
Board at each site, was consistent with the principles of the
Declaration of Helsinki. All patients or their authorized representa-
tives provided written informed consent. While the trial was con-
ducted in several countries, this analysis was limited to patients
treated in the USA because of differences in outpatient antimicrobial
treatment approaches outside of the USA. Data included patient
location during treatment with the study drug, including any changes
in level of care (Table 1), and treatment outcome. Comparisons were
made to elucidate the impact of changes in level of care.
To be enrolled in the SAB/IE study, patients had to be at least
18 years of age and have had at least one blood culture growing
S. aureus within 2 days before the ﬁrst administration of the study
drug. Exclusion criteria included CLCR ,30 mL/min and the pre-
sence of known osteomyelitis, polymicrobial bacteraemia or pneu-
monia. Patients were evaluated at the end of therapy and 42 days
after the end of therapy to determine treatment success and rule out
relapse.
12 Patients with persisting/relapsing S. aureus infection,
death or clinical failure within 6 weeks of the end of therapy were
considered clinical failures. This analysis did not consider adminis-
trative reasons for failure that were included in the primary efﬁcacy
analysis of the original study, such as discontinuation caused by an
adverse event, administration of a potentially effective non-study
drug and no blood culture drawn at test-of-cure visit.
12
The protocol allowed completion of therapy in community care
settings. The decision to pursue CoPAT was based on the investi-
gators’ assessment of patients’ clinical stability, including the
absence of surgical indications.
13 Psychosocial characteristics and
the availability of appropriate community care services were also
considered. Patients receiving their full course of antimicrobial
therapy in the hospital setting, categorized as inpatient antimicro-
bial therapy (IPAT), were compared with those receiving some
portion of antimicrobial therapy outside of the hospital, categor-
ized as CoPAT. For the purposes of this analysis, IPAT was
deﬁned as all care in one or more of the following locations:
(i) hospital intensive care unit; (ii) hospital step-down unit; and
(iii) general hospital ward. CoPAT was deﬁned as initial inpatient
treatment followed by care in one or more of the following
locations: (i) skilled nursing facility; (ii) assisted-living setting,
nursing home or rehabilitation centre; (iii) at-home treatment with
assistance; and (iv) at-home treatment without assistance.
Escalation of care was deﬁned as any transfer to a location provid-
ing a higher level of care, as ordered above, for example, from
ward to intensive care unit or home to ward.
iv access for CoPAT was selected by individual physicians and
established prior to hospital discharge. Antibiotics were pre-mixed
by an infusion pharmacy and delivered every 48 h. Vancomycin was
administered as an infusion over at least 1 h; daptomycin and semi-
synthetic penicillin doses were infused over 30 min. Vancomycin
and daptomycin infusions were administered by nurses in all set-
tings. Patients receiving semi-synthetic penicillins at home were
treated via an ambulatory infusion pump programmed by home care
nurses to deliver doses at 4 h intervals around the clock. Nurses
monitored patients’ overall status and vital signs daily during
CoPAT; physicians were notiﬁed of changes in conditions. Except
for end of therapy and test-of-cure visits, physician ofﬁce follow-up
was not standardized. Per study protocol, blood chemistries, com-
plete blood counts and creatine phosphokinase levels were obtained
weekly in all care settings.
Patient characteristics and outcomes were analysed using Fisher’s
exact test for categorical data and a two-sample t-test or the
Wilcoxon rank sum test for continuous data. All tests were two-sided.
All analyses were performed using SAS
w software, Version 9.1.
Results
Patient characteristics
Two hundred US patients were included in this analysis, with
103 (51.5%) receiving part of their treatment outside of the hos-
pital setting (CoPAT). The majority of CoPAT patients (69/103,
67.0%) were discharged home without assistance and two others
(1.9%) went home with assistance. Nineteen of the 103 CoPAT
patients (18.4%) were discharged to a skilled nursing facility,
while 13/103 (12.6%) were treated in an assisted-living setting,
nursing home or rehabilitation centre. The study database did
not systematically record the types of venous access devices
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catheters were the preferred means of securing venous access.
Compared with patients who received all care in the hospital,
CoPAT patients were younger (median age 50 versus 54 years,
P¼0.028) and tended to have fewer cases of endocardial in-
volvement (8.7% versus 18.6%; P¼0.061) as well as less pre-
existing valvular heart disease (7.8% versus 15.5%, P¼0.120).
The two groups had a similar distribution of diagnoses
(Figure 1) and a similar distribution of study medications.
Baseline demographic, diagnostic and treatment characteristics
are shown in Table 1.
Other differences between the treatment groups included a
trend towards higher baseline CLCR in the CoPAT patients
(median 92.1 versus 86.0 mL/min, P¼0.064) and a trend
towards a lower percentage of CoPAT patients with fever at
day 4 of treatment (9.7% versus 18.8%, P¼0.101). Among
CoPAT patients, baseline characteristics were similar for those
receiving either daptomycin or comparator treatment (Table 2).
Patient outcomes
Among CoPAT patients, clinical success rates were similar
regardless of study medication, with 45/50 (90.0%) daptomycin
patients and 44/53 (83.0%) comparator patients experiencing
clinical success. For IPAT patients, clinical success was
observed in 26/50 (52.0%) daptomycin patients and 28/47
(59.6%) comparator patients. Thus, it is justiﬁed to combine the
treatment groups for analysis of outcomes.
CoPAT patients received longer courses of study antibiotics
with a mean of 25.4 days (range 9–74 days) compared with
13.5 days (range 1–43) in the IPAT group (P,0.001), and a
higher proportion of CoPAT patients completed therapy as part
of the study (90.3% versus 45.4%, P,0.001). CoPAT patients
received a mean of 14.9 days of therapy outside the hospital
setting (Table 1). The shorter duration of study treatment for
IPAT patients was inﬂuenced by early discontinuations: there
were 53 (54.6%) versus 10 (9.7%) in the CoPAT group. The
most common reason for discontinuation was adverse events,
which accounted for 25/53 (47.2%) IPAT and 8/10 (80.0%)
CoPAT patient discontinuations. The adverse events responsible
for discontinuation, including rash, infection, renal failure and
creatine phosphokinase elevation, are listed in Table 3. IPAT
patients whose study participation was terminated prior to the
Table 1. Demographics, diagnosis and treatment characteristics by
treatment location
Characteristic
CoPAT
(n¼103)
IPAT
(n¼97) P
a
Study drug
daptomycin 50 (48.5%)
b 50 (51.5%) 0.687
c
vancomycin
d 30 (29.1%) 23 (23.7%)
SSP
d 23 (22.3%) 24 (24.7%)
Age (years)
median 50.0 54.0 0.028
e
range 21–90 24–91
Male 60 (58.3%) 59 (60.8%) 0.774
Race
white 66 (64.1%) 55 (56.7%) 0.070
c
black 30 (29.1%) 25 (25.8%)
other 7 (6.8%) 17 (17.5%)
Weight (kg)
median 81.7 78.2 0.493
e
range 49.9–129.0 53.5–131.4
MRSA 37 (35.9%) 39 (40.6%)
f 0.560
CLCR (mL/min)
median 92.1 86.0 0.064
e
range 29.4–277.0 17.9–200.8
CLCR ,50 mL/min 12 (11.7%) 12 (12.4%) .0.999
Evidence of endocardial
involvement
9 (8.7%) 18 (18.6%) 0.061
Injection drug use 26 (25.2%) 22 (22.7%) 0.741
Pre-existing valvular heart
disease
8 (7.8%) 15 (15.5%) 0.120
Fever on day 4 10 (9.7%) 18 (18.8%)
g 0.101
Completed treatment 93 (90.3%) 44 (45.4%) ,0.001
Duration of treatment (days)
mean (SD) 25.4 (12.34) 13.5 (9.49) ,0.001
h
range 9–74 1–43
Days inpatient during treatment
mean (SD) 10.5 (7.27) 13.5 (9.49) 0.014
h
range 2–38 1–43
Days outpatient during treatment
mean (SD) 14.9 (10.08) 0 NA
range 1–49 —
Experienced  1 SAE 48 (46.6%) 52 (53.6%) 0.396
CoPAT, outpatient parenteral antimicrobial therapy in the community setting;
IPAT, patients receiving their full course of therapy in the hospital setting;
SSP, semi-synthetic penicillin; MRSA, methicillin-resistant S. aureus; NA,
not applicable; SAE, serious adverse event.
aFisher’s exact test, unless otherwise speciﬁed.
bNo. (%), unless otherwise speciﬁed.
cOverall Fisher’s exact test for characteristic.
dWith or without concomitant gentamicin.
eWilcoxon’s rank sum test.
fn¼96 for MRSA.
gn¼96 for fever (inpatient): fever on day 4 was possible but not deﬁnitive
on day 4 for six patients in the inpatient group who were considered to have
not had a fever.
ht-test.
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Figure 1. Final diagnosis by CoPAT or IPAT treatment. CoPAT, outpatient
parenteral antimicrobial therapy in the community setting; IPAT, patients
receiving their full course of therapy in the hospital setting; uBAC,
uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE,
right-sided infective endocarditis; LIE, left-sided infective endocarditis.
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priate, but speciﬁc information regarding types and duration of
additional therapy was not part of the study database.
A higher rate of clinical success at the test-of-cure visit was
observed among CoPAT patients (89/103, 86.4%) compared
with that among IPAT patients (54/97, 55.7%) (P,0.001). Four
of the 103 CoPAT patients (3.9%) experienced persisting or
relapsing S. aureus infection, compared with 15/97 IPAT
patients (15.5%, P¼0.007). Fewer deaths occurred in the
CoPAT group (4/103, 3.9%) compared with those in the IPAT
group (18/97, 18.6%; P¼0.001) (Table 4).
Escalation of care
Twice as many CoPAT patients (22/103, 21.4%) were trans-
ferred to a higher level of care during their course of treatment
compared with those transferred among IPAT patients (10/97,
Table 4. Clinical outcomes for CoPAT patients versus IPAT
patients
Clinical outcome 6 weeks
after end of therapy
CoPAT
a
(n¼103)
IPAT
(n¼97) P
b
Clinical success 89 (86.4%)
c 54 (55.7%) ,0.001
Failure 10 (9.7%) 26 (26.8%)
Non-evaluable 4 (3.9%) 17 (17.5%)
Death 4 (3.9%) 18 (18.6%) 0.001
CoPAT, outpatient parenteral antimicrobial therapy in the community setting;
IPAT, patients receiving their full course of therapy in the hospital setting.
aInpatients who were partly treated outside a hospital.
bFisher’s exact test.
cNo. (%).
Table 2. Demographic, diagnosis and treatment characteristics by
treatment group among CoPAT patients
Characteristic
Daptomycin
(n¼50)
Comparator
a
(n¼53)
Age (years)
median 46.5 52.0
range 21–81 25–90
Gender
male 31 (62.0%)
b 29 (54.7%)
Race
white 26 (52.0%) 40 (75.5%)
black 19 (38.0%) 11 (20.8%)
other 5 (10.0%) 2 (3.8%)
Weight (kg)
median 82.1 80.0
range 55.0–129.0 49.9–124.8
MRSA 18 (36.0%) 19 (35.8%)
CLCR (mL/min)
median 108.1 86.4
range 29.4–246.9 31.0–277.0
CLCR ,50 mL/min 4 (8.0%) 8 (15.1%)
Evidence of endocardial
involvement
4 (8.0%) 5 (9.4%)
Injection drug use 14 (28.0%) 12 (22.6%)
Pre-existing valvular heart
disease
3 (6.0%) 5 (9.4%)
Fever on day 4 3 (6.0%) 7 (13.2%)
Completed treatment 46 (92.0%) 47 (88.7%)
Duration of treatment (days)
mean (SD) 25.9 (13.31) 25.0 (11.46)
range 11–74 9–57
Days inpatient during treatment
mean (SD) 10.7 (7.06) 10.3 (7.52)
range 5–38 2–35
Days outpatient during treatment
mean (SD) 15.2 (10.08) 14.7 (10.18)
range 2–46 1–49
Final diagnosis
uBAC 10 (20.0%) 17 (32.1%)
cBAC 27 (54.0%) 24 (45.3%)
RIE 11 (22.0%) 8 (15.1%)
LIE 2 (4.0%) 4 (7.5%)
Experienced  1 SAE 23 (46.0%) 25 (47.2%)
CoPAT, outpatient parenteral antimicrobial therapy in the community setting;
MRSA, methicillin-resistant S. aureus; uBAC, uncomplicated bacteraemia;
cBAC, complicated bacteraemia; RIE, right-sided infective endocarditis;
LIE, left-sided infective endocarditis; SAE, serious adverse event.
aComparator treatment was semi-synthetic penicillin/gentamicin or vancomy-
cin/gentamicin.
bNo. (%), unless otherwise speciﬁed.
Table 3. Adverse events leading to discontinuation
CoPAT
(n¼8)
a
IPAT
(n¼25)
a
Anaphylactic reaction 0 1
Skin
b 44
Red man syndrome 0 1
Diabetic gastroparesis 1 0
Vomiting not otherwise speciﬁed 0 1
Blood creatine phosphokinase increased 1 2
Cardiovascular
c 04
Hypoxia 0 1
Infection
d 03
Fever 0 2
Renal failure 2 3
Sepsis 0 2
Thrombocytopenia 0 1
aNumber of discontinuations due to an adverse event.
bSkin includes dermatitis bullous, dermatitis medicamentosa, erythematous
rash, vesicular rash and rash not otherwise speciﬁed.
cCardiovascular includes cardiac arrest (two patients), cerebrovascular acci-
dent and circulatory collapse.
dInfection includes osteomyelitis not otherwise speciﬁed, staphylococcal
pneumonia and staphylococcal bacteraemia.
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(P¼0.036) (Table 5). Hospital readmission was required for 18
of the 103 (17.5%) CoPAT patients. As shown in Table 6, the
reasons for hospital readmission were diverse. Four patients
(22.2% of the readmissions and 3.9% of CoPAT patients) were
readmitted for reasons related to their initial infection, including
osteomyelitis or relapsed SAB. Problems related to provision of
treatment in the post-acute care setting led to the readmission of
three patients, two of whom relapsed with iv drug use (IVDU)
and one of whom developed Clostridium difﬁcile colitis. Other
medical conditions leading to readmission included pneumonia
in three patients and a myriad of other conditions, including
unknown reasons, which were each experienced by a single
patient. Of the 18 CoPAT patients readmitted to the hospital
during the study, half subsequently returned to treatment in the
CoPAT setting.
IVDU was associated with an increased risk of hospital re-
admission for CoPAT patients, with 7/26 (26.9%) IVDU patients
requiring readmission, compared with 11/77 (14.3%) non-IVDU
patients requiring readmission. The use of iv drugs during
therapy was documented in two of the seven readmitted IVDU
patients. Also of note was the fact that a higher proportion of
patients with right-sided IE (6/19, 31.6%), though not statisti-
cally signiﬁcant, required hospital readmission compared with
those with other ﬁnal diagnoses (Table 6). Five of the six re-
admitted patients with right-sided IE were iv drug users (four
complicated right-sided IE and one uncomplicated right-sided IE).
Discussion
Numerous publications have described clinical experiences with
OPAT in various countries, in some cases over extended periods
of time, showing it to be generally safe, effective, convenient
and economically beneﬁcial when properly administered.
8,11,14–18
These publications typically draw data from local or national
OPAT registries or from the databases of hospitals or other
facilities offering outpatient iv antimicrobial therapy services
and that describe the experience of tens of thousands of patients.
However, despite the voluminous data on OPAT, the availability
of data from controlled clinical trials is meagre, especially
among patients treated for MRSA infection,
19,20 and it is poorer
still in patients with SAB/IE.
Limited published data on outpatient iv antimicrobial therapy
for various kinds of bacterial infections (not limited to
S. aureus) indicate a hospital readmission rate of  8% to
30%,
21,22 a range that includes the 17.5% rate observed in the
present study. It should be noted that these data are based on a
variety of different infections—including prosthetic infections,
osteomyelitis, septic arthritis and soft tissue infections—that
may be expected to have lower rates of readmission than SAB.
Of additional interest are the results from a recently published
UK study by Matthews et al.,
14 w h i c hc o m p a r e d‘ s e l f -
administered’ OPAT (i.e. parenteral antibiotic therapy administered
by patients, relatives or caretakers) with OPAT administered by
community-based healthcare workers. This study, which analysed
Table 5. Escalation of care and patient location at last dose of study drug
Characteristic CoPAT (n¼103) IPAT (n¼97)
Transferred to higher level of care at any time during treatment 22 (21.4%)
a–c 10 (10.3%)
No. times readmitted to hospital to complete treatment with study drug
one 17 (16.5%) NA
two 1 (1.0%) NA
Returned to outpatient care after readmission 9 (50.0%)
d NA
Reasons readmitted
factors relating to initial infection 4 (22.2%) NA
other conditions
e 11 (61.1%) NA
issues relating to provision of treatment at home 3 (16.7%)
f NA
Location for last dose of study drug
for patients who completed treatment 93 (90.3%) 44 (45.4%)
in hospital setting 8 (7.8%)
g 44 (45.4%)
as an outpatient 85 (82.5%) 0
for patients who prematurely discontinued treatment 10 (9.7%) 53 (54.6%)
in hospital setting 2 (1.9%)
g 53 (54.6%)
as an outpatient 8 (7.8%) 0
CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of
therapy in the hospital setting; NA, not applicable.
aNo. (%).
bP¼0.036, Fisher’s exact test.
cOne patient had increased level of care within post-acute care but was not readmitted to hospital. Three patients had esca-
lation of inpatient care prior to post-acute care.
dBased on the 18 patients who were readmitted to hospital.
eUnderlying disease or new problems not related to the initial infection. See Table 6.
fOne patient was readmitted twice for the same problem related to delivery of treatment at home. See Table 6.
gPatients readmitted to hospital.
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signiﬁcant difference between the two approaches in either hospital
readmissions (10.5% versus 12.6%, P¼0.3) or complications.
14
It should be noted that 39% and 26.3%, respectively, of patients
whose therapy was self-administered or given by healthcare
workers were being treated for S. aureus infections.
14
In 1992, it was estimated that  300000 Americans are
treated annually with outpatient iv antimicrobial therapy;
23 it is
likely that the number of courses of therapy has increased since
then. The savings associated with outpatient treatment in such a
large number of patients could be signiﬁcant, since hospital stay
represents  60% to 90% of the total cost of treating serious
infections.
24,25 Data from the present study support ﬁndings from
previous studies of decreased length of hospital stay, which has
been shown to reduce costs and would also likely reduce the
risk of nosocomial infection.
16,18 Detailed economic analysis of
this study is ongoing.
Previous experience with OPAT suggests that success is most
likely in patients with uncomplicated infections and in situations
where appropriate agents and means of delivery are avail-
able.
26,27 While there is a certain variability in the requirements
for managing IE with outpatient therapy, guidelines created by
the American Heart Association and endorsed by the Infectious
Diseases Society of America (IDSA) list the following minimal
conditions for treatment in the home setting:
27 reliable caretaker
support and easy access to a hospital; regular visits by a home
infusion nurse; and regular consultation (e.g. weekly) with a
physician for assessment of clinical status. In the case of
S. aureus IE, more stringent guidelines have been suggested. These
include: hospitalization during the initial 2 week critical period
(and possibly for a continuation phase of up to 2–4 weeks),
patient education regarding potential complications as well as
methods of contacting medical staff, proximity to the hospital,
and biweekly ofﬁce visits or home visits from the healthcare
team.
13
The optimal approach to outpatient treatment of SAB/IE for
patients with a history of IVDU remains unclear. iv drug users
typically respond well to treatment and have a similar, and poss-
ibly lower, mortality rate compared with other bacteraemia
patients.
28–30 The high cure rate among iv drug users with endo-
carditis has been partly attributed to the majority of infections
involving the tricuspid valve, which responds particularly well
to antimicrobial therapy as opposed to those involving the aortic
or mitral valves.
31 Among iv drug users, the rate of compli-
cations does not appear to be higher overall compared with
other patients, although limited data suggest a higher rate of vas-
cular events.
28 The decision to discharge iv drug users to com-
munity settings is complicated by the potential for relapse of
IVDU and suboptimal adherence to recommendations. These
concerns may lead physicians to choose treatment settings with
greater levels of supervision and structure. In this study, the rate
of hospital readmission among iv drug users on CoPAT was
nearly double that of CoPAT patients who were not iv drug
users. It is worth noting that of the seven iv drug users re-
admitted to the hospital, two were found to have resumed use of
iv drugs. Caution should be exercised in the selection and man-
agement of iv drug users who are candidates for CoPAT, as
active drug use leads to safety and efﬁcacy problems.
The current IDSA guidelines emphasize that when CoPAT
therapy is considered, the antimicrobial agent selected should be
effective against the causative pathogen, preferably dosed once
daily, have a minimal adverse event proﬁle, limited therapeutic
drug monitoring and be stable in dosing formulations.
32 The
clinical trial upon which this analysis was based compared stan-
dard therapy (semi-synthetic penicillins or vancomycin with
initial low-dose gentamicin) for SAB/IE with daptomycin, the
ﬁrst of a new class of cyclic lipopeptide antimicrobials.
12 The
standard treatment options may pose logistical challenges when
used for CoPAT. Semi-synthetic penicillins are considered stan-
dard therapy for SAB/IE caused by MSSA but may be difﬁcult
to administer in the outpatient setting because of the need for
multiple daily doses (up to six times per day), as well as toler-
ability issues such as rash and diarrhoea.
8,33,34 Vancomycin is
Table 6. Patient status and factors related to hospital readmission
among CoPAT patients
Characteristic
CoPAT patients
(n¼103)
No. of post-acute care patients
readmitted
a
18/103 (17.5%)
b
Reasons for readmission
Factors relating to initial infection (n¼4)
osteomyelitis 2/18 (11.1%)
relapsed S. aureus bacteraemia 1/18 (5.6%)
embolic stroke 1/18 (5.6%)
Other conditions (n¼11)
pneumonia 3/18 (16.7%)
urinary tract infection 1/18 (5.6%)
fever of unknown origin 1/18 (5.6%)
gout 1/18 (5.6%)
seizures (history of seizure disorder) 1/18 (5.6%)
sarcoid 1/18 (5.6%)
gastroparesis 1/18 (5.6%)
left against medical advice 1/18 (5.6%)
unknown 1/18 (5.6%)
Issues relating to receipt of treatment at home (n¼3)
drug use 2/18 (11.1%)
C. difﬁcile colitis 1/18 (5.6%)
Study drug
daptomycin 9/50 (18.0%)
vancomycin 4/30 (13.3%)
semi-synthetic penicillin 5/23 (21.7%)
Final diagnosis
uBAC 2/27 (7.4%)
cBAC 10/51 (19.6%)
RIE 6/19 (31.6%)
LIE 0/6
Intravenous drug user
no 11/77 (14.3%)
yes 7/26 (26.9%)
CoPAT, outpatient parenteral antimicrobial therapy in the community setting;
uBAC, uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE,
right-sided infective endocarditis; LIE, left-sided infective endocarditis.
aOne patient was readmitted twice for reasons relating to treatment at home.
bNo. (%).
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1039considered by many to be standard treatment for SAB/IE caused
by MRSA, but it requires infusion over at least 1 h and thera-
peutic drug monitoring. In addition, a growing body of literature
suggests inconsistent vancomycin efﬁcacy because of changes in
S. aureus susceptibility.
35–38 Alternative agents such as dapto-
mycin, which are conducive to use in the outpatient setting, are
needed, particularly for MRSA infections.
8,31,39–42 Daptomycin
is an effective alternative to standard therapy,
12,42 and its dosing
schedule (once every 24 h for patients with a CLCR  30 mL/min
or once every 48 h when the creatinine is ,30 mL/min) is
convenient for CoPAT. After reconstitution and dilution in iv
solution, daptomycin is stable under refrigeration for 48 h per
the current FDA-approved package insert.
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Limitations
The comparison of clinical outcomes between patients treated in
the CoPAT and IPAT settings must be understood in the context
of the patients’ severity of illness. Candidates for outpatient anti-
microbial therapy typically are stable patients at low risk of
developing complications. The lower clinical success rate
observed in the IPAT group in this study would be expected
because of the greater severity of illness in these patients. One
strength of this analysis is that it is based on data from a ran-
domized, controlled clinical trial. However, the trial was not
prospectively designed to assess outpatient versus inpatient care,
and the retrospective nature of the current analysis may result in
bias. In addition, as patients were followed only while receiving
the study drug, treatment after study drug discontinuation was
not captured.
It should be noted that outpatient antimicrobial therapy was
provided at no cost as part of the trial, thereby potentially limit-
ing the cost-related biases typically inherent in studies compar-
ing inpatient with outpatient treatment. This aspect of the trial
does not reﬂect real-life practice, where reimbursement for out-
patient therapy varies depending on an individual’s insurance
coverage, and this may limit generalization of the study results.
Furthermore, in analysing data only from US centres participat-
ing in the trial, the results draw on a smaller patient population
than that of the original study, and may apply primarily in the
USA.
Conclusions
The present study demonstrates that stable patients with SAB/IE
can successfully complete iv antibacterial therapy in the outpa-
tient setting. Proper monitoring of these patients is necessary, as
changes in their conditions may necessitate an escalation of
care. This study further demonstrates that daptomycin is an
appropriate treatment option for patients with SAB/IE who are
completing therapy in the outpatient setting. Additional research
is warranted to deﬁne selection criteria for patients with SAB/IE
who may be candidates for outpatient therapy.
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